Jean Daniel Tissot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8375096/publications.pdf Version: 2024-02-01

		70961	114278
186	5,346	41	63
papers	citations	h-index	g-index
223	223	223	4858
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The EHA Research Roadmap: Transfusion Medicine. HemaSphere, 2022, 6, e670.	1.2	2
2	Sulfenylome analysis of pathogenâ€inactivated platelets reveals the presence of cysteine oxidation in integrin signaling pathway and cytoskeleton regulation. Journal of Thrombosis and Haemostasis, 2021, 19, 233-247.	1.9	7
3	Image- and Fluorescence-Based Test Shows Oxidant-Dependent Damages in Red Blood Cells and Enables Screening of Potential Protective Molecules. International Journal of Molecular Sciences, 2021, 22, 4293.	1.8	4
4	Hypoxia and hypocapnia storage of \hat{I}^3 -irradiated red cell concentrates. Blood Transfusion, 2021, 19, 300-308.	0.3	1
5	Irreversible oxidations of platelet proteins after riboflavin-UVB pathogen inactivation. Transfusion Clinique Et Biologique, 2020, 27, 36-42.	0.2	12
6	Erythroferrone as a sensitive biomarker to detect stimulation of erythropoiesis. Drug Testing and Analysis, 2020, 12, 261-267.	1.6	19
7	Medical student education in transfusion medicine, part II: Moving forward to building up a "Know How" education program in transfusion medicine for under-graduate medical students. Transfusion and Apheresis Science, 2020, 59, 102879.	0.5	3
8	Transfusion medicine: Overtime paradigm changes and emerging paradoxes. Transfusion Clinique Et Biologique, 2020, 27, 262-267.	0.2	2
9	Restoration of Physiological Levels of Uric Acid and Ascorbic Acid Reroutes the Metabolism of Stored Red Blood Cells. Metabolites, 2020, 10, 226.	1.3	12
10	Detection of Stimulated Erythropoiesis by the RNA-Based 5'-Aminolevulinate Synthase 2 Biomarker in Dried Blood Spot Samples. Clinical Chemistry, 2019, 65, 1563-1571.	1.5	21
11	Theoretical and experimental ethics: advocacy for blood donors and beneficiaries of blood transfusions. Transfusion Medicine, 2018, 28, 261-262.	0.5	7
12	Oxidative stress and antioxidant defenses during blood processing and storage of erythrocyte concentrates. Transfusion Clinique Et Biologique, 2018, 25, 96-100.	0.2	37
13	Linking transfusion and ecology is not so futile after all: A holistic reappraisal of transfusion and immunity. Transfusion Clinique Et Biologique, 2018, 25, 82-83.	0.2	0
14	General overview of blood products in vitro quality: Processing and storage lesions. Transfusion Clinique Et Biologique, 2018, 25, 269-275.	0.2	10
15	Medical student education in transfusion medicine: Proposal from the "European and Mediterranean initiative in transfusion medicine― Transfusion and Apheresis Science, 2018, 57, 593-597.	0.5	12
16	Transfusion and refusal: trials and tribulations. International Journal of Clinical Transfusion Medicine, 2018, Volume 6, 15-20.	0.8	1
17	Low-Frequency Blood Group Antigens in Switzerland. Transfusion Medicine and Hemotherapy, 2018, 45, 239-250.	0.7	8
18	Generation of procoagulant collagen―and thrombinâ€activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage. Transfusion, 2018, 58, 2395-2406.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Compte rendu du cinquième séminaire d'éthique de l'Institut national de la transfusion sanguineÂ: quelles relations interpersonnelles sont-elles convoquées aux différentes étapes de la chaîne transfusionnelleÂ?. Ethics, Medicine and Public Health, 2018, 6, 139-145.	0.5	2
20	Proteomics of Stored Red Blood Cell Membrane and Storage-Induced Microvesicles Reveals the Association of Flotillin-2 With Band 3 Complexes. Frontiers in Physiology, 2018, 9, 421.	1.3	36
21	Blood and Blood Components: From Similarities to Differences. Frontiers in Medicine, 2018, 5, 84.	1.2	25
22	Plasma for direct therapeutic use, for today and tomorrow: A short critical overview. Transfusion Clinique Et Biologique, 2018, 25, 281-286.	0.2	10
23	How to mitigate the risk of inducing transfusion-associated adverse reactions. Transfusion Clinique Et Biologique, 2018, 25, 262-268.	0.2	18
24	Editorial: Transfusion Medicine and Blood. Frontiers in Medicine, 2018, 5, 355.	1.2	2
25	Quantification of stored red blood cell fluctuations by time-lapse holographic cell imaging. Biomedical Optics Express, 2018, 9, 4714.	1.5	29
26	About collection of blood and clinical use of blood components and ethical considerationsThoughts from the Ethical Committee of the National Institute for Blood Transfusion, France. Hematologie, 2018, 24, 233-241.	0.0	0
27	Proteomics of blood plasma/serum samples stored in biobanks: insights for clinical application. Expert Review of Proteomics, 2017, 14, 643-644.	1.3	1
28	Appliquées à la transfusion, quelles sont les bases philosophiques de la bioéthique�. Ethics, Medicine and Public Health, 2017, 3, 216-220.	0.5	2
29	Automatic washing of thawed haematopoietic progenitor cell grafts: a preclinical evaluation. Vox Sanguinis, 2017, 112, 367-378.	0.7	13
30	Short-Term versus Long-Term Blood Storage. New England Journal of Medicine, 2017, 376, 1091-1094.	13.9	5
31	The antioxidant capacity of erythrocyte concentrates is increased during the first week of storage and correlated with the uric acid level. Vox Sanguinis, 2017, 112, 638-647.	0.7	45
32	The storage lesions: From past to future. Transfusion Clinique Et Biologique, 2017, 24, 277-284.	0.2	42
33	Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion. International Journal of Molecular Sciences, 2017, 18, 387.	1.8	32
34	The 3-phase evolution of stored red blood cells and the clinical trials: an obvious relationship. Blood Transfusion, 2017, 15, 188.	0.3	23
35	Red blood cells ageing markers: a multi-parametric analysis. Blood Transfusion, 2017, 15, 239-248.	0.3	61
36	Transfusion and ecology: sense, nonsense, or missense?. Blood Transfusion, 2017, 15, 274-275.	0.3	5

3

#	Article	IF	CITATIONS
37	Small-Scale Perfusion Bioreactor of Red Blood Cells for Dynamic Studies of Cellular Pathways: Proof-of-Concept. Frontiers in Molecular Biosciences, 2016, 3, 11.	1.6	10
38	Antioxidant power as a quality control marker for completeness of amotosalen and ultraviolet A photochemical treatments in platelet concentrates and plasma units. Transfusion, 2016, 56, 1819-1827.	0.8	17
39	Proteomics of the red blood cell carbonylome during blood banking of erythrocyte concentrates. Proteomics - Clinical Applications, 2016, 10, 257-266.	0.8	44
40	Effects of oral supplementation of iron on hepcidin blood concentrations among nonâ€anaemic female blood donors: a randomized controlled trial. Vox Sanguinis, 2016, 110, 166-171.	0.7	6
41	Autologous Blood Transfusion in Sports: Emerging Biomarkers. Transfusion Medicine Reviews, 2016, 30, 109-115.	0.9	38
42	"Save lives―arguments might not be as effective as you think: A randomized field experiment on blood donation. Transfusion Clinique Et Biologique, 2016, 23, 59-63.	0.2	12
43	Impact of blood transfusion on gene expression in human reticulocytes. American Journal of Hematology, 2016, 91, E460-1.	2.0	9
44	Ethics and blood donation: A marriage of convenience. Presse Medicale, 2016, 45, e247-e252.	0.8	12
45	Cysteine redox proteomics of the hemoglobinâ€depleted cytosolic fraction of stored red blood cells. Proteomics - Clinical Applications, 2016, 10, 883-893.	0.8	15
46	ls proteomics still knockin' on the hematological door?. Proteomics - Clinical Applications, 2016, 10, 765-766.	0.8	3
47	Red blood cell microvesicles: a storage lesion or a possible salvage mechanism. ISBT Science Series, 2016, 11, 171-177.	1.1	5
48	Metabolomic profiling highlights oxidative damages in platelet concentrates treated for pathogen inactivation and shows protective role of urate. Metabolomics, 2016, 12, 1.	1.4	18
49	Hepcidin as a new biomarker for detecting autologous blood transfusion. American Journal of Hematology, 2016, 91, 467-472.	2.0	33
50	Blood donation and/or donated blood acceptance: The different stakeholders' ethical considerations. Ethics, Medicine and Public Health, 2016, 2, 213-219.	0.5	4
51	Urinary diâ€(2â€ethylhexyl) phthalate metabolites for detecting transfusion of autologous blood stored in plasticizerâ€free bags. Transfusion, 2016, 56, 571-578.	0.8	22
52	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	1.7	67
53	Improving platelet transfusion safety: biomedical and technical considerations. Blood Transfusion, 2016, 14, 109-22.	0.3	44

#	Article	IF	CITATIONS
55	Differences between calcium-stimulated and storage-induced erythrocyte-derived microvesicles. Transfusion and Apheresis Science, 2015, 53, 153-158.	0.5	42
56	In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVBâ€ŧreated platelet concentrates. Transfusion, 2015, 55, 2219-2230.	0.8	31
57	Bloodletting for nonâ€medical reasons: what about safety and quality?. Transfusion Medicine, 2015, 25, 424-425.	0.5	2
58	Early and current days of transfusion medicine help to understand longevity and particularities of transfusion therapy in the elderly. Transfusion and Apheresis Science, 2015, 52, 261.	0.5	1
59	In vitro assays and clinical trials in red blood cell aging: Lost in translation. Transfusion and Apheresis Science, 2015, 52, 270-276.	0.5	61
60	In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step. Blood Transfusion, 2015, 13, 255-64.	0.3	27
61	Storage lesion: History and perspectives. World Journal of Hematology, 2015, 4, 54.	0.1	2
62	Selling Donations: Ethics and Transfusion Medicine. , 2015, , 285-296.		2
63	Transfusion safety from the viewpoint of a musical quintet. Blood Transfusion, 2015, 13, 687.	0.3	7
64	The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Reviews, 2014, 28, 235-241.	2.8	106
65	Prevalence of restless legs syndrome in female blood donors 1Âweek after blood donation. Vox Sanguinis, 2014, 107, 44-49.	0.7	12
66	Physiology of Iron Metabolism. Transfusion Medicine and Hemotherapy, 2014, 41, 213-221.	0.7	176
67	Large scale inkjet-printing of carbon nanotubes electrodes for antioxidant assays in blood bags. Journal of Electroanalytical Chemistry, 2014, 717-718, 61-68.	1.9	48
68	Molecular RHD screening of RhD negative donors can replace standard serological testing for RhD negative donors. Transfusion and Apheresis Science, 2014, 50, 163-168.	0.5	18
69	Proteome Changes in Platelets After Pathogen Inactivation—An Interlaboratory Consensus. Transfusion Medicine Reviews, 2014, 28, 72-83.	0.9	80
70	LC-MS/MS Analysis and Comparison of Oxidative Damages on Peptides Induced by Pathogen Reduction Technologies for Platelets. Journal of the American Society for Mass Spectrometry, 2014, 25, 651-661.	1.2	30
71	Donation: Blood. , 2014, , 1-10.		0
72	Problématiques éthiques anciennes et nouvelles en transfusion sanguine. Hematologie, 2014, 20, 166-171.	0.0	0

#	Article	IF	CITATIONS
73	The picture of Dorian Gray: news from the red blood cell storage lesion. Blood Transfusion, 2014, 12, 293-5.	0.3	1
74	Red blood cell–derived microparticles isolated from blood units initiate and propagate thrombin generation. Transfusion, 2013, 53, 1744-1754.	0.8	150
75	Iron and transfusion medicine. Blood Reviews, 2013, 27, 289-295.	2.8	18
76	Blood donation associated risks: data from a Swiss regional haemovigilance program. Transfusion Medicine, 2013, 23, 269-271.	0.5	3
77	Validation of hepcidin quantification in plasma using LC–HRMS and discovery of a new hepcidin isoform. Bioanalysis, 2013, 5, 2509-2520.	0.6	31
78	Blood microvesicles: From proteomics to physiology. Translational Proteomics, 2013, 1, 38-52.	1.2	69
79	CLINICAL APPLICATIONS Gel Electrophoresis. , 2013, , .		Ο
80	Development of a high throughput PCR to detect Coxiella burnetii and its application in a diagnostic laboratory over a 7-year period. New Microbes and New Infections, 2013, 1, 6-12.	0.8	43
81	CLINICAL APPLICATIONS Electrophoresis. , 2013, , .		Ο
82	Myths: history, blood, sex and money. Blood Transfusion, 2013, 11, 1-3.	0.3	27
83	Red Blood Cell Microparticles: Clinical Relevance. Transfusion Medicine and Hemotherapy, 2012, 39, 342-347.	0.7	72
84	Subcellular fractionation of stored red blood cells reveals a compartment-based protein carbonylation evolution. Journal of Proteomics, 2012, 76, 181-193.	1.2	74
85	Proteomic analysis of Intercept-treated platelets. Journal of Proteomics, 2012, 76, 316-328.	1.2	36
86	Unusual colours of plasma. British Journal of Haematology, 2012, 156, 419-419.	1.2	3
87	Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Medicine, 2012, 10, 8.	2.3	53
88	Red blood cell microparticles and blood group antigens: an analysis by flow cytometry. Blood Transfusion, 2012, 10 Suppl 2, s39-45.	0.3	22
89	Proteomics of blood and derived products: what's next?. Expert Review of Proteomics, 2011, 8, 717-737.	1.3	23
90	Analysis and clinical relevance of microparticles from red blood cells. Current Opinion in Hematology, 2010, 17, 571-577.	1.2	81

#	Article	IF	CITATIONS
91	Blood proteomics. Journal of Proteomics, 2010, 73, 466-467.	1.2	6
92	Stored red blood cells: A changing universe waiting for its map(s). Journal of Proteomics, 2010, 73, 374-385.	1.2	72
93	Biomarker Analysis of Stored Blood Products: Emphasis on Pre-Analytical Issues. International Journal of Molecular Sciences, 2010, 11, 4601-4617.	1.8	31
94	Bacterial Contamination of Platelet Concentrates: Perspectives for the Future: Table 1. Laboratory Medicine, 2010, 41, 301-305.	0.8	7
95	Pre-analytical and methodological challenges in red blood cell microparticle proteomics. Talanta, 2010, 82, 1-8.	2.9	43
96	Microparticles in stored red blood cells: submicron clotting bombs?. Blood Transfusion, 2010, 8 Suppl 3, s31-8.	0.3	36
97	Bacterial contamination of platelet concentrates: pathogen detection and inactivation methods. Hematology Reports, 2009, 1, 5.	0.3	9
98	Severe neonatal hyporegenerative anemia due to anti-Vw (anti-MNS9) alloantibody. Journal of Perinatal Medicine, 2009, 37, 422-4.	0.6	5
99	The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials, 2009, 10, 4.	0.7	9
100	Associations of serum EBV DNA and gammopathy with postâ€ŧransplant lymphoproliferative disease. Clinical Transplantation, 2009, 23, 74-82.	0.8	18
101	Primitive liver cancers: epidemiology and geographical study in France. European Journal of Gastroenterology and Hepatology, 2009, 21, 984-989.	0.8	20
102	Oxidation of proteins: Basic principles and perspectives for blood proteomics. Proteomics - Clinical Applications, 2008, 2, 142-157.	0.8	55
103	Microparticles in stored red blood cells: an approach using flow cytometry and proteomic tools. Vox Sanguinis, 2008, 95, 288-297.	0.7	161
104	Application of proteomics to hematology: the revolution is starting. Expert Review of Proteomics, 2008, 5, 375-379.	1.3	20
105	Omics meets hypothesis-driven research. Thrombosis and Haemostasis, 2008, 100, 738-746.	1.8	20
106	Methods for Human CD8+ T Lymphocyte Proteome Analysis. Methods in Molecular Biology, 2008, 484, 45-65.	0.4	2
107	Omics meets hypothesis-driven research. Partnership for innovative discoveries in vascular biology and angiogenesis. Thrombosis and Haemostasis, 2008, 100, 738-46.	1.8	6
108	Plasma/serum proteomics: pre-analytical issues. Expert Review of Proteomics, 2007, 4, 363-370.	1.3	52

#	Article	IF	CITATIONS
109	Proteomics of Amniotic Fluid. , 2007, , 415-436.		2
110	Role of enzyme-treated cells in RBC antibody screening using the gel test: a study of anti-RH1, -RH2, and -RH3 antibodies. Journal of Clinical Laboratory Analysis, 2007, 21, 61-66.	0.9	2
111	Proteomic analyses of amniotic fluid: Potential applications in health and diseases. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 850, 336-342.	1.2	27
112	Proteomic and transcriptomic analysis of human CD8+ T lymphocytes over-expressing telomerase. Proteomics - Clinical Applications, 2007, 1, 299-311.	0.8	3
113	Proteomics and transfusion medicine: Future perspectives. Proteomics, 2006, 6, 5605-5614.	1.3	28
114	Clinical proteomics: Study of a cryogel. Proteomics, 2006, 6, 3958-3960.	1.3	8
115	Peptidomics and proteomics studies of transformed lymphocytes from patients mutated for the eukaryotic initiation factor 2Bâ^†. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 840, 20-28.	1.2	4
116	Proteome analysis of human plasma and amniotic fluid by Off-Gelâ,,¢ isoelectric focusing followed by nano-LC-MS/MS. Electrophoresis, 2006, 27, 1169-1181.	1.3	99
117	Two-Dimensional Gel Electrophoresis Based Technologies for Potential Biomarkers Identification in Amniotic Fluid: A Simple Model. Protein and Peptide Letters, 2006, 13, 959-963.	0.4	4
118	Haemovigilance in a general university hospital: need for a more comprehensive classification and a codification of transfusion-related events. Vox Sanguinis, 2005, 88, 22-30.	0.7	29
119	Two-stage Off-Gel? isoelectric focusing: Protein followed by peptide fractionation and application to proteome analysis of human plasma. Electrophoresis, 2005, 26, 1174-1188.	1.3	115
120	Recent advances in blood-related proteomics. Proteomics, 2005, 5, 3019-3034.	1.3	173
121	SPS' Digest: The Swiss Proteomics Society selection of proteomics articles. Proteomics, 2005, 5, 3045-3047.	1.3	Ο
122	The role of proteomics in the assessment of premature rupture of fetal membranes. Clinica Chimica Acta, 2005, 360, 27-36.	0.5	59
123	Proteomic Studies of Human Lymphocytes: New Insights into HIV Lymphocyte Infection?. , 2004, , 245-262.		2
124	â€~Agglutination and flocculation' of stem cells collected by apheresis due to cryofibrinogen. Bone Marrow Transplantation, 2004, 33, 765-767.	1.3	11
125	Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics, 2004, 4, 881-891.	1.3	45
126	Identification of swiprosin 1 in human lymphocytes. Proteomics, 2004, 4, 2216-2220.	1.3	53

#	Article	IF	CITATIONS
127	Proteomics: Haematological Perspectives. , 2004, , 57-99.		1
128	Plasticity of protein expression during culture of fetal skin cells. Electrophoresis, 2003, 24, 1281-1291.	1.3	14
129	Three years of haemovigilance in a general university hospital. Transfusion Medicine, 2003, 13, 63-72.	0.5	39
130	Identification of biologic markers of the premature rupture of fetal membranes: Proteomic approach. Proteomics, 2003, 3, 1521-1525.	1.3	108
131	High resolution proteome analysis of cryoglobulins using Fourier transform-ion cyclotron resonance mass spectrometry. Proteomics, 2003, 3, 1425-1433.	1.3	43
132	Cryoglobulin/albumin complexes in a patient with severe autoimmune syndrome. Scandinavian Journal of Rheumatology, 2003, 32, 367-373.	0.6	6
133	IgM are associated to SpÎ \pm (CD5 antigen-like). Electrophoresis, 2002, 23, 1203-1206.	1.3	51
134	Identification of specific proteins in different lymphocyte populations by proteomic tools. Proteomics, 2002, 2, 105-111.	1.3	26
135	The immunoglobulinopathies: From physiopathology to diagnosis. Proteomics, 2002, 2, 813.	1.3	25
136	Electrophoretic characteristics of monoclonal immunoglobulin G of different subclasses. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 771, 355-368.	1.2	10
137	Human Peripheral Blood Leukocyte Engraftment into SCID Mice: Critical Role of CD4+ T Cells. Cellular Immunology, 2001, 211, 8-20.	1.4	7
138	The diversity of antigen-specific antibodies in humans and in two xenochimeric SCID mouse models. Electrophoresis, 2000, 21, 2463-2475.	1.3	3
139	Preparation and analysis of fetal liver extracts. Bone Marrow Transplantation, 2000, 26, 667-671.	1.3	12
140	Human adult tonsil xenotransplantation into SCID mice for studying human immune responses and B cell lymphomagenesis. Experimental Hematology, 2000, 28, 177-192.	0.2	10
141	How should we manage fibromyalgia?. Annals of the Rheumatic Diseases, 2000, 59, 490-490.	0.5	3
142	A "missed" cryoglobulin: the importance of in vitro calcium concentration. Annals of the Rheumatic Diseases, 2000, 59, 490a-490.	0.5	7
143	Hypocomplementemic panniculitis with paraprotein. Journal of Rheumatology, 2000, 27, 1091-5.	1.0	2
144	Microheterogeneity of Serum Glycoproteins in Patients with Chronic Alcohol Abuse Compared with Carbohydrate-deficient Glycoprotein Syndrome Type I. Clinical Chemistry, 1999, 45, 1408-1413.	1.5	54

1.2

16

#	Article	IF	CITATIONS
145	Haematological parameters of parvovirus B19 infection in 13 fetuses with hydrops foetalis. British Journal of Haematology, 1999, 104, 925-927.	1.2	52
146	The Direct Antiglobulin Test: Still a Place for the Tube Technique?. Vox Sanguinis, 1999, 77, 223-226.	0.7	21
147	Hepatitis Virus-Related and Ethanol-Induced Chronic Liver Disease with or without Cryoglobulins - Is There a Difference Concerning Clinical or Laboratory Manifestation?. Infection, 1999, 27, 248-251.	2.3	5
148	Micropurification and two-dimensional polyacrylamide gel electrophoresis of immunoglobulins for studying the clonal diversity of antigen-specific antibodies. Journal of Immunological Methods, 1999, 227, 137-148.	0.6	8
149	Two-dimensional electrophoretic analysis of cryoproteins: A report of 335 samples. Electrophoresis, 1999, 20, 606-613.	1.3	30
150	Microheterogeneity of serum glycoproteins in patients with chronic alcohol abuse compared with carbohydrate-deficient glycoprotein syndrome type I. Clinical Chemistry, 1999, 45, 1408-13.	1.5	9
151	Monomeric complement-activating IgG paraproteins. Journal of Immunology, 1999, 163, 6924-32.	0.4	4
152	The direct antiglobulin test: still a place for the tube technique?. Vox Sanguinis, 1999, 77, 223-6.	0.7	6
153	Electrophoretic analyses in a case of monoclonal Î ³ chain disease. Electrophoresis, 1998, 19, 1771-1773.	1.3	7
154	Hepatitis C Virus (HCV) Infection: Serum Rheumatoid Factor Activity and HCV Genotype Correlate With Cryoglobulin Clonality. Blood, 1998, 92, 3486-3488.	0.6	12
155	Hepatitis C virus (HCV) infection: serum rheumatoid factor activity and HCV genotype correlate with cryoglobulin clonality. Blood, 1998, 92, 3486-7.	0.6	5
156	Clinical implications of the types of cryoglobulins determined by two-dimensional polyacrylamide gel electrophoresis. Haematologica, 1998, 83, 693-700.	1.7	9
157	Large-field high-resolution x-ray microscope for studying laser plasmas. Review of Scientific Instruments, 1997, 68, 3412-3420.	0.6	35
158	Hematological Features of Fetal Triploidy: A Report of 11 Cases. Neonatology, 1997, 72, 279-283.	0.9	7
159	Microheterogeneity of serum glycoproteins and their liver precursors in patients with carbohydrate-deficient glycoprotein syndrome type I: Apparent deficiencies in clusterin and serum amyloid P. Translational Research, 1997, 129, 412-421.	2.4	34
160	Apolipoprotein J deficiency in types I and IV carbohydrate-deficient glycoprotein syndrome (glycanosis) Tj ETQq0	0 0 rgBT / 1.3	Overlock 10
161	Human Immunoglobulins Produced in hu-PBL-SCID Mice Are Polyclonal Early after Xenotransplantation. Cellular Immunology, 1996, 167, 241-248.	1.4	11

Blood smears and prenatal diagnosis. British Journal of Haematology, 1996, 95, 278-280.

#	Article	IF	CITATIONS
163	Role of two-dimensional electrophoretic analysis in the diagnosis and characterization of IgD monoclonal gammopathy. Allergy: European Journal of Allergy and Clinical Immunology, 1995, 50, 664-670.	2.7	9
164	Analysis of immunoglobulins by two-dimensional gel electrophoresis. Journal of Chromatography A, 1995, 698, 225-250.	1.8	34
165	No evidence for protein modifications in fresh frozen plasma after photochemical treatment: an analysis by high-resolution two-dimensional electrophoresis. British Journal of Haematology, 1994, 86, 143-146.	1.2	32
166	Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. Journal of Immunological Methods, 1994, 173, 63-75.	0.6	72
167	Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood, 1994, 84, 1851-6.	0.6	23
168	Human liver protein map: Update 1993. Electrophoresis, 1993, 14, 1216-1218.	1.3	77
169	Plasma and red blood cell protein maps: Update 1993. Electrophoresis, 1993, 14, 1223-1226.	1.3	129
170	Two-dimensional electrophoresis as an aid in the analysis of the clonality of immunoglobulins. Electrophoresis, 1993, 14, 1366-1371.	1.3	13
171	Pattern variations of polyclonal and monoclonal immunoglobulins of different isotypes analyzed by high-resolution two-dimensional electrophoresis. Electrophoresis, 1993, 14, 227-234.	1.3	23
172	Clonal imbalances of plasma/serum immunogloblin production in infants. Electrophoresis, 1993, 14, 245-247.	1.3	16
173	Effect of Prestorage Leukocyte Reduction on Proteins of Platelets Obtained by Apheresis. Vox Sanguinis, 1993, 65, 279-285.	0.7	7
174	Analysis of plasma/serum immunoglobulins by two-dimensional polyacrylamide gel electrophoresis. Clinical Immunology Newsletter, 1993, 13, 97-101.	0.1	5
175	Effect of Prestorage Leukocyte Reduction on Proteins of Platelets Obtained by Apheresis. Vox Sanguinis, 1993, 65, 279-285.	0.7	5
176	Polypeptide marker and disease patterns found while mapping proteins in ascitis. Biomedical Applications, 1992, 582, 87-92.	1.7	7
177	Plasma protein map: An update by microsequencing. Electrophoresis, 1992, 13, 707-714.	1.3	144
178	Human liver protein map: A reference database established by microsequencing and gel comparison. Electrophoresis, 1992, 13, 992-1001.	1.3	132
179	Clonality of cold agglutinins in patients with hemolytic anemia: An analysis by high-resolution two-dimensional gel electrophoresis. American Journal of Hematology, 1992, 40, 171-175.	2.0	9
180	Clonal imbalances of serum immunoglobulins after allogeneic bone marrow transplantation: an analysis by high-resolution two-dimensional gel electrophoresis. Bone Marrow Transplantation, 1992, 10, 347-53.	1.3	13

#	Article	IF	CITATIONS
181	MONO-OLIGOCLONAL PRODUCTION OF IMMUNOGLOBULINS IN A CHILD WITH THE WISKOTT-ALDRICH SYNDROME. British Journal of Haematology, 1990, 75, 436-438.	1.2	14
182	Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma Journal of Lipid Research, 1988, 29, 1557-1571.	2.0	96
183	Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. Journal of Lipid Research, 1988, 29, 1557-71.	2.0	77
184	Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. International Journal of Cancer, 1984, 34, 295-302.	2.3	66
185	Présentation de cas cliniques de la Clinique Universitaire de Genève. Dermatology, 1984, 169, 282-290.	0.9	1
186	Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase Journal of Clinical Investigation, 1982, 70, 1320-1323.	3.9	71